Navigation Links
Ampio Awarded US and Canadian Patents that will Bolster the Commercialization of Optina™ for the treatment of Diabetic Macular Edema (DME)
Date:4/27/2012

e eyes is often an early form of diabetic retinopathy that causes significant vision loss.  Almost all Type 1 diabetics and more than 60% of Type 2 diabetics will develop retinopathy. There is no effective daily drug treatment for diabetic retinopathy other than general measures, such as controlling blood sugar, hypertension, blood lipids, etc. Due to the global diabetes epidemic, diabetic retinopathy is recognized as a high, unmet medical need that would benefit from having oral therapeutic options available. The only treatments available for macular edema now are laser therapy, injection or implantation of drugs into or around the eyeball (not approved in the US or Canada). To our knowledge, Optina™ is the only proposed oral treatment for this condition.

About Optina™
Optina™ is an orally administered ultra low dose of danazol, for the treatment of diabetic macular edema (DME).  Ampio's Chief Scientific Officer discovered an unexpected activity in his investigation of the mechanism of action of danazol: very low doses reversed inflammation-induced increases in the permeability of blood vessels, thus reducing vascular leakage.  Dr. Bar-Or subsequently managed in-vitro studies that suggested this effect may reduce the vasogenic edema produced by various vascular leak syndromes, including diabetic macular edema (DME) which can impair vision and cause blindness. The specific Optina dosages used in the trial are proprietary and subject to multiple patent filings.

Danazol, a derivative of the synthetic steroid ethisterone, was approved by the FDA in the 1970s for endometriosis and, more recently, for other chronic indications, including hereditary angioedema, ITP and fibrocystic disease of the breast.

About Ampio
Ampio Pharmaceuticals, Inc. develops innovative proprietary drugs for inflammation, eye disease, kidney disease, CNS disease, metabolic disease and male sexual dysfun
'/>"/>

SOURCE Ampio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Ampio Strengthens Patent Protection for Lead Drug Ampion™
2. Ampio Announces Positive Preliminary Update on the Optina™ Clinical Trial to Treat Diabetic Macular Edema and Decision to Conclude the Study Ahead of Schedule
3. Champions Oncology Reports Fiscal 2012 Third Quarter Financial Results
4. Ampio Pharmaceuticals Reports Full-Year 2011 Financial Results and Milestone Highlights for 2011
5. Ampio Pharmaceuticals Schedules 2012 Outlook Webcast
6. Executive Changes at Ampio
7. Ampio Pharmaceuticals Schedules Webcast to Update Shareholders
8. Ampio Pharmaceuticals Announces Registered Direct Common Stock Offering of Approximately $9.436 Million
9. Ampio Responds to Recent Publications by Anonymous Short Sellers
10. Champions Oncology Reports Fiscal 2012 Second Quarter Financial Results
11. FDA Advisory Panel Recommends Against Approval of Champion® Heart Failure Management System for Patients With Heart Failure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... , July 30, 2015  EP Global ... executives have recently contacted the Company about discussing ... as early as Monday, August 3, 2015.  Novartis ... as saying that the coming electronic contact lens ... dollars over the next several years.  Novartis partnered ...
(Date:7/30/2015)... PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced ... second quarter ending June 30, 2015. ... We are excited to be near the completion of ... with topline results expected in the fourth quarter," stated ... Inc. "Translarna is now commercially available in 12 countries ...
(Date:7/30/2015)... -- Growth of the U.S. nonprescription market is primarily driven ... to the OTC market. Due to an increasingly favorable ... activity over the next five years with several all ... entering the market into existing categories. If ... those with low to moderate likelihood), the market is ...
Breaking Medicine Technology:PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 10Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 2Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 3
(Date:7/31/2015)... Wilmington, DE (PRWEB) , ... July 31, 2015 ... ... long term care client base, with the recent implementation of Microsoft Dynamics GP ... provider in the industry, Intellitec is now supporting senior living communities in 16 ...
(Date:7/30/2015)... ... 31, 2015 , ... When responsible for the care of an aging loved ... through your mind: What happens if mom falls? Who will remind Dad to take ... plans. , But not taking time away from caregiving responsibilities can lead to bigger ...
(Date:7/30/2015)... ... July 31, 2015 , ... On July 22nd the Bradenton Herald ... plausible solutions for controlling the heroin outbreak. Ultimately the committee expressed lack of funding, ... perpetuating the heroin crisis in North Florida. The task force has proposed to instate ...
(Date:7/30/2015)... , ... July 30, 2015 , ... ... (C-Path), and TransCelerate BioPharma, Inc. are pleased to announce that data standards for ... published for use on the CDISC website . These three Therapeutic Area ...
(Date:7/30/2015)... ... July 30, 2015 , ... Women's dating coach Simone Myers ... for women interested in improving their love lives using specific "lines" designed to ... to the public early this morning, has drawn praise from several dating and ...
Breaking Medicine News(10 mins):Health News:Intellitec Solutions Expands Long term Care ERP Offerings to Maine 2Health News:Aging Life Care Association™ Experts Offer Tips for Caregivers in Need of Vacation Time 2Health News:Aging Life Care Association™ Experts Offer Tips for Caregivers in Need of Vacation Time 3Health News:Manatee County’s Opioid Task Force Calls for More Funding and Face to Face Counseling After Overdose 2Health News:Manatee County’s Opioid Task Force Calls for More Funding and Face to Face Counseling After Overdose 3Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 2Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 3Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 4Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 5Health News:Lovetraction Lines - Review Examining Simone Myers' New Online Course Released 2
... Westchester, Ill. A study in the Feb. 1 issue ... impairments in older men with obstructive sleep apnea (OSA) are ... , A modest link between OSA severity and ... longer statistically significant after controlling for total sleep time. ...
... Researchers at Stanford University School of Medicine have identified ... Blocking the expression of the protein slowed or prevented ... vulnerable to the conditions of low oxygen that occur ... inhibiting the protein inhibits the tumor,s ability to grow," ...
... radiotherapy delivery systems cut dose, side effects after rare ... The best way to treat a rare form of ... by targeted radiotherapy, U.S. researchers say. , Ependymoma affects ... but concerns about side effects have limited the use ...
... Reported; No Other Products Within the NutriSystem Food Portfolio ... NutriSystem Inc., a leading provider of weight management products ... its NutriSystem-branded Peanut Butter Granola Bar due to the ... include all peanut products manufactured from January 1, 2007 ...
... of small arteries at the surface of the brain redirects ... to tissue starved of nutrients and oxygen following a stroke, ... optimistic news," said David Kleinfeld, a physics professor at the ... in animal models of stroke. , Damage from stroke can ...
... Officials with Baylor Health Care System ... the Baylor Research Institute (BRI) as vice ... 1. (Photo: http://www.newscom.com/cgi-bin/prnh/20090130/DC65143 )Under his leadership, ... of its unique research technologies in areas ...
Cached Medicine News:Health News:Daytime impairments in older men with obstructive sleep apnea are related to total sleep time 2Health News:Stanford study prevents pancreatic tumor growth in mice by inhibiting key protein 2Health News:Stanford study prevents pancreatic tumor growth in mice by inhibiting key protein 3Health News:Aggressive Treatment Effective in Kids' Brain Cancer 2Health News:NutriSystem Expands Voluntary United States Recall of Peanut Butter Granola Breakfast Bar to Include Canada Due to Possible Peanut Corporation of America (PCA) Contamination and Potential Health Risk 2Health News:NutriSystem Expands Voluntary United States Recall of Peanut Butter Granola Breakfast Bar to Include Canada Due to Possible Peanut Corporation of America (PCA) Contamination and Potential Health Risk 3Health News:Mesh-like network of arteries adjusts to restore blood flow to stroke-injured brain 2Health News:Bernard Brigonnet Joins Baylor Research Institute as Vice President and Chief Operating Officer 2Health News:Bernard Brigonnet Joins Baylor Research Institute as Vice President and Chief Operating Officer 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: